El interés público prevalece: las resoluciones de precio y reembolso de medicamentos son confidenciales

This article analyzes the latest rulings by the Contentious-Administrative Chamber of the National High Court regarding the confidentiality of pricing and reimbursement decisions for two medicinal products. Specifically, the reasoning of the judgments to conclude that these documents must remain confidential and cannot be accessed through Law 19/2013, of December 9, on Transparency, Access to Public Information, and Good Governance are analyzed.